AIDS Therapies (Human Serum Albumin)

Antiviral Effect of Modified Serum Albumin May Prevent Drug Resistance

Published in Blood Weekly, March 24th, 1997

Modified human serum albumin (HSA) may have potential for antiviral therapy use in individuals infected with HIV.

Martijn Groenink, Netherlands Red Cross Blood Transfusion Service, Amsterdam, Netherlands, and colleagues previously reported on the antiviral capacity of HSA that was modified by the introduction of a single (Suc-HSA) or two carboxylic groups (Aco-HSA) per lysine residue, yielding strongly negatively charged polypeptides. More recently, they reported the antiviral effect of the modified HSAs on replication of primary HIV-1 isolates that differed with respect to synctium-inducing (SI) capacity and cell tropism ("Potent Inhibition of Replication of Primary...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1997-03-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry